Akebia Therapeutics (AKBA) Times Interest Earned (2013 - 2026)
Akebia Therapeutics' (AKBA) quarterly Times Interest Earned came in at -$1.32 in Q1 2026, down 120.56% year-on-year from $6.44 in Q1 2025, and up 74.01% on a QoQ basis from -$5.09 in Q4 2025.
Akebia Therapeutics (AKBA) Times Interest Earned (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has 14 years of Times Interest Earned data on file, last reported at -$1.32 in Q1 2026.
- On a quarterly basis, Times Interest Earned fell 120.56% year-over-year to -$1.32 in Q1 2026; TTM through Mar 2026 was $1.49, a 133.39% increase from a year earlier, with the FY2025 full-year figure at $1.07, up 919.92% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$1.32, up from -$5.09 in the prior quarter.
- Over the last five years, Times Interest Earned for AKBA reached as high as $30.77 in Q4 2024 and fell as low as -$24.0 in Q3 2022.
- Historically, Times Interest Earned has averaged -$2.76 across 5 years, with a median of -$5.09 in 2025.
- Across the five-year window, Times Interest Earned slumped 144.55% in 2023 and jumped 2943.18% in 2024, its largest moves.
- Year by year, Times Interest Earned stood at $6.54 in 2022, then slumped by 84.53% to $1.01 in 2023, then jumped by 2943.18% to $30.77 in 2024, then slumped by 116.55% to -$5.09 in 2025, then jumped by 74.01% to -$1.32 in 2026.
- Per Business Quant data, the three most recent Times Interest Earned figures were -$1.32 in Q1 2026, -$5.09 in Q4 2025, and $0.29 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 13.44 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.81 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.18 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -0.07 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.33 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.11 |
| 10 | Akebia Therapeutics | 325.80 Mn | 163.20 Mn | 41.25 Mn | -1.32 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.32 |
| Dec 31, 2025 | -5.09 |
| Sep 30, 2025 | 0.29 |
| Jun 30, 2025 | 0.50 |
| Mar 31, 2025 | 6.44 |
| Dec 31, 2024 | 30.77 |
| Sep 30, 2024 | -7.36 |
| Jun 30, 2024 | -5.45 |
| Mar 31, 2024 | -10.67 |
| Dec 31, 2023 | 1.01 |
| Sep 30, 2023 | -9.31 |
| Jun 30, 2023 | -5.62 |
| Mar 31, 2023 | -14.22 |
| Dec 31, 2022 | 6.54 |
| Sep 30, 2022 | -24.00 |
| Jun 30, 2022 | 12.62 |
| Mar 31, 2022 | -22.07 |
| Dec 31, 2021 | -23.34 |
| Sep 30, 2021 | -20.33 |
| Jun 30, 2021 | -29.39 |